Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia. Results of a phase 3 trial. ( Kollef MH. et al. )
Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial.
| Dr Jean-Pierre Bru This randomised, controlled, double-blind, non-inferiority trial was conducted at 263 hospitals in 34 countries. Eligible patients were adults, undergoing mechanical … Suite